Dementia and cognitive impairment

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Abstract  Background Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug ‐ cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine ‐ are widely licensed for dementia due to Alzheimer’s disease, and rivastigmine is also licensed for Parkinson’s disease dementia. […]

Share

Remotely delivered information, training and support for informal caregivers of people with dementia

Abstract Background Many people with dementia are cared for at home by unpaid informal caregivers, usually family members. Caregivers may experience a range of physical, emotional, financial and social harms, which are often described collectively as caregiver burden. The degree of burden experienced is associated with characteristics of the caregiver, such as gender, and characteristics […]

Share

Souvenaid for Alzheimer’s disease

Abstract Background Souvenaid is a dietary supplement with a patented composition (Fortasyn Connect™)which is intended to be used by people with Alzheimer’s disease (AD). It has been designed to support the formation and function of synapses in the brain, which are thought to be strongly correlated with cognitive function. If effective, it might improve symptoms […]

Share

Pharmacotherapies for sleep disturbances in dementia

Abstract Background Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant carer distress, increased healthcare costs, and institutionalisation. Although non‐drug interventions are recommended as the first‐line approach to managing these problems, drug treatment is often sought and used. However, […]

Share

Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings

Abstract Background People with dementia living in the community, that is in their own homes, are often not engaged in meaningful activities. Activities tailored to their individual interests and preferences might be one approach to improve quality of life and reduce challenging behaviour. Objectives To assess the effects of personally tailored activities on psychosocial outcomes […]

Share

Aromatherapy for dementia

Abstract Background Medications licensed for the treatment of dementia have limited efficacy against cognitive impairment or against the distressed behaviours (behavioural and psychological symptoms, or behaviour that challenges) which are also often the most distressing aspect of the disorder for caregivers. Complementary therapies, including aromatherapy, are attractive to patients, practitioners and families, because they are […]

Share

Simulated presence therapy for dementia

Abstract Background Dementia is a common and serious neuropsychiatric syndrome, characterised by progressive cognitive and functional decline. The majority of people with dementia develop behavioural disturbances, also known as behavioural and psychological symptoms of dementia (BPSD). Several non‐pharmacological interventions have been evaluated to treat BPSD in people with dementia. Simulated presence therapy (SPT), an intervention […]

Share

Addenbrooke’s Cognitive Examination III (ACE‐III) and mini‐ACE for the detection of dementia and mild cognitive impairment

Abstract Background The number of new cases of dementia is projected to rise significantly over the next decade. Thus, there is a pressing need for accurate tools to detect cognitive impairment in routine clinical practice. The Addenbrooke’s Cognitive Examination III (ACE‐III), and the mini‐ACE are brief, bedside cognitive screens that have previously reported good sensitivity […]

Share

Animal-assisted therapy for dementia

Abstract Background Dementia is a chronic condition which progressively affects memory and other cognitive functions, social behaviour, and ability to carry out daily activities. To date, no treatment is clearly effective in preventing progression of the disease, and most treatments are symptomatic, often aiming to improve people’s psychological symptoms or behaviours which are challenging for […]

Share

Cerebrolysin for vascular dementia

Abstract Background Although vascular dementia is the second most common cause of dementia globally, evidence‐based treatments are still lacking. Cerebrolysin is a porcine brain‐derived preparation that is said to have neurotrophic and neuroprotective activity. In many parts of the world Cerebrolysin, given as a series of daily intravenous infusions, is used as a potential intervention […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share